The Future of thePoint-of-Care (POC) Coagulation Testing Devices Market: Growth Trends, Market Size, and Opportunities to Watch
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Drivers Are Shaping the Growth and Development of thePoly ADP-Ribose Polymerase (PARP) Inhibitor Market?
The increasing prevalence of ovarian cancer is expected to propel the growth of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer is rising due to genetic, environmental, and hormonal factors. PARP inhibitors target DNA repair in ovarian cancer treatment, particularly for patients with BRCA mutations. The World Ovarian Cancer Coalition projected a 70% increase in ovarian cancer-related deaths by 2024. Therefore, the rising prevalence of ovarian cancer is contributing to the growth of the PARP inhibitor market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15637&type=smp
#How Does the ProjectedPoly ADP-Ribose Polymerase (PARP) Inhibitor Market Growth Compare Over the Forecast Period?
The poly ADP-ribose polymerase (PARP) inhibitor market size has seen rapid growth, rising from $8.39 billion in 2024 to $9.41 billion in 2025 at a CAGR of 12.1%. Key drivers include clinical research advancements, regulatory approvals, market competition, drug combinations, and patient advocacy efforts.
The poly ADP-ribose polymerase (PARP) inhibitor market is expected to grow to $14.67 billion by 2029, with a CAGR of 11.7%. This growth is driven by expanded indications, personalized medicine, biomarker development, and emerging markets. Trends include immunotherapy, precision medicine, and AI in drug discovery.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15637
Which Cutting-Edge Market Trends Are Expected to Drive thePoly ADP-Ribose Polymerase (PARP) Inhibitor Market’s Growth?
Major companies in the poly ADP-ribose polymerase (PARP) inhibitor market are developing generic PARP inhibitors to provide tailored cancer treatments for patients with specific genetic mutations. For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib, a PARP inhibitor under the IBYRA brand, targeting genetic mutations in breast, ovarian, prostate, and pancreatic cancers, offering an effective treatment option for HRD-positive or BRACA mutation patients.
What Are the Leading Market Players Impacting thePoly ADP-Ribose Polymerase (PARP) Inhibitor Market’s Growth Trend?
Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc
Order Your Report Now For A Swift Delivery:
How Are the Key Segments of the Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Driving Opportunities and Innovations?
The poly ADP-ribose polymerase (PARP) inhibitor market covered in this report is segmented –
1) By Drug Type: Talazoparib, Veliparib, Olaparib, Other Drug Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Ovarian Cancer, Breast Cancer, Other Applications
4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Talazoparib: Talazoparib For Breast Cancer, Talazoparib For Ovarian Cancer, Talazoparib For Prostate Cancer, Talazoparib For Other Cancers
2) By Veliparib: Veliparib For Breast Cancer, Veliparib For Ovarian Cancer, Veliparib For Non-Small Cell Lung Cancer (Nsclc), Veliparib For Other Cancers
3) By Olaparib: Olaparib For Breast Cancer (Her2-negative), Olaparib For Ovarian Cancer (Brca-mutated), Olaparib For Prostate Cancer (Brca-Mutated), Olaparib For Pancreatic Cancer (Brca-Mutated), Olaparib For Other Cancers
4) By Other Drug Types: Niraparib, Rucaparib, Pembrolizumab (Combination Therapy With Parp Inhibitors), Other Parp Inhibitors (Emerging Drugs In Clinical Trials)
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=15637&type=smp
What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of thePoly ADP-Ribose Polymerase (PARP) Inhibitor Market?# Market Expansion?
North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market 2025, By The Business Research Company:
Interleukin Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024
HER2 Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
